Dyadic International vs Molecular Partners
DYAI and MOLN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DYAI and MOLN compare
Dyadic International grew revenue faster over the last twelve months (−8.0% versus −100% for Molecular Partners).
Dyadic International scores higher on the StockData Score (7 against 1 for Molecular Partners), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DYAI | MOLN |
|---|---|---|
| Size and price | ||
| Market cap | $11.9M | – |
| Share price | $0.327 | $2.94 |
| Change, 1 year | −65.3% | −28.8% |
| Change, 5 years | −91.5% | −71.9% |
| Beta (5Y) | 1.18 | 0.89 |
| Employees | 5 | 34 |
| StockData Score | ||
| Total score | 7 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.1× | – |
| Growth | ||
| Revenue growth (TTM) | −8.0% (better) | −100% |
| Revenue growth, 5Y average | 14.0% | – |
| Profitability | ||
| Gross margin | 16.2% | – |
| Operating margin | −195% | – |
| Net margin | −200% | – |
| Financial health | ||
| Interest coverage | – | −11.5× |
| Current ratio | 1.65 | 7.27 (better) |
| Altman Z-score | −22.79 | – |
| Piotroski F-score | 2 | – |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 12.7% | 8.9% |
| Held by insiders | 28.0% | 0.00% |
| Insider net buying, 12 months | −$125K | – |
| Short interest, % of float | 0.32% | – |
Go deeper
- DYAI stock overview
- DYAI income statement
- DYAI valuation and score
- MOLN stock overview
- MOLN income statement
- MOLN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.